Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study

Core Insights - Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is gaining positive analyst sentiment due to encouraging updates from the Phase 1b PIONEER study for pociredir in sickle cell disease, with 80% of analysts being bullish and a median price target of $18.00, indicating a 90.40% upside potential [2] Group 1: Analyst Ratings and Price Targets - Truist raised its price target for Fulcrum Therapeutics from $14 to $18, maintaining a "Buy" rating, citing positive reception of partial Cohort 4 data as a significant factor [3] - Bank of America increased its price target from $6 to $7 but maintained an "Underperform" rating, projecting a potential 2029 launch for pociredir with expected peak sales of $1.5 billion by 2038 [4] Group 2: Clinical Study Updates - Fulcrum Therapeutics reported positive initial results from the 20 mg dose cohort of the PIONEER study, highlighting significant increases in fetal hemoglobin, a clear dose-response relationship, and a favorable safety profile with no serious side effects [5] Group 3: Financial Developments - The company priced a public offering on December 10, 2025, expected to raise $175 million in gross proceeds, enhancing its balance sheet flexibility [6]